Sleep Month in Review: June 2025

In June, sleep medicine updates from SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies in Seattle from June 8 – 11th, highlighted advances in pharmacotherapy and evolving guidelines. AXS-12 showed phase 3 efficacy for narcolepsy, while new obstructive sleep apnea (OSA) treatments—tirzepatide, AD109, and potassium channel blockers—offered personalized options beyond CPAP. Updated restless legs syndrome (RLS) guidelines advised against dopamine agonists due to augmentation risk, favoring iron and alpha-2-delta therapies